Antiplatelet therapy in neuroendovascular therapeutics.
Our understanding of the pharmacology of antiplatelet therapy continues to evolve rapidly. Although the existing data are primarily generated in the setting of interventional and preventative cardiology studies, these data may be extrapolated to guide the rational application of these agents in neuroendovascular procedures. Platelet function testing represents an increasingly available and practical method by which to verify the adequacy of therapy and guide clinical decision making. The optimal application of these agents will undoubtedly improve the risk profile of neuroendovascular procedures, increase the success rate of acute stroke intervention, and facilitate more effective secondary stroke prevention.
Fiorella
David
D
Cleveland Clinic Foundation, 9500 Euclid Avenue, S80, Cleveland, OH 44195, USA. fioreld@ccf.org
Thiabolt
Lucie
L
Albuquerque
Felipe C
FC
Deshmukh
Vivek R
VR
McDougall
Cameron G
CG
Rasmussen
Peter A
PA
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D002532:Intracranial Aneurysm / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D020767:Intracranial Thrombosis / Q000188:drug therapy* / Q000601:surgery; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011859:Radiography; D015607:Stents; D013988:Ticlopidine / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin